CONTROVERSIA
Portrait not available

Born in India · Nationality American — Business / pharmacie / Insys Therapeutics / opioïdes / fraude santé / justice fédérale

John Kapoor

Business and billionairesScience, medicine and health

Fiche documentée couvrant 9 controverses, dont « Formation en pharmacie et chimie médicinale » et « Création d'EJ Financial Enterprises et investissements pharmaceutiques ».

Are you concerned? Right of reply

Profile No. 4177 · Updated on 13 October 2026

9Documented controversies+ 5 background events
9Sources
1Formal charge · all time1 followed by a conviction
1Conviction

§ Legal statuses reflect the documented sources as of the date shown; they replace neither court decisions nor the presumption of innocence. Counts are not a rating. Methodology

I. Documented controversies

01

2022

La Cour suprême refuse d'examiner son recours

Civil / administrative proceedings

Après la confirmation en appel, Kapoor saisit la Cour suprême; sa demande de certiorari est rejetée en 2022.

State of the evidence
Documented
Attribution
Protagonist is the complainant

Sources · 2

  1. [1]
    Supreme Court of the United StatesBrief in Opposition — Kapoor v. United StatesCourt recordVery high reliability
  2. [2]
    U.S. District Court for the District of Delaware / JustiaInsys Liquidation Trust v. Kapoor — Proposed FindingsCourt recordHigh reliability

Last verified: 19 September 2026

Add to this entry

Case · 6 documented stages

First Circuit confirme le verdict et rétablit les predicate findings, mais renvoie restitution/confiscation

Conviction
02

25 août 2021

First Circuit confirme le verdict et rétablit les predicate findings, mais renvoie restitution/confiscation

Conviction

La cour d'appel confirme les verdicts et peines, rétablit des findings que le district court avait écartés et annule/renvoie certains ordres de restitution et de confiscation pour recalcul.

Sources · 1

  1. [1]
    U.S. Court of Appeals for the First Circuit / JustiaUnited States v. Simon, No. 20-1368Court decisionVery high reliability

Last verified: 19 September 2026

Add to this entry

03

23 janvier 2020

Peine de 66 mois de prison

Conviction

Kapoor est condamné à 66 mois de prison et trois ans de supervised release dans le dossier Insys.

Legal status — source text
sentenced
Attribution
Accused

Sources · 2

  1. [1]
    U.S. Department of Justice, District of MassachusettsFounder and Former Chairman of the Board of Insys Therapeutics Sentenced to 66 Months in PrisonOfficial statementVery high reliability
  2. [2]
    U.S. Court of Appeals for the First Circuit / JustiaUnited States v. Simon, No. 20-1368Court decisionVery high reliability

Last verified: 19 September 2026

Add to this entry

04

2019

Procès : système de rémunération des prescripteurs et fraude de remboursement

Conviction

Les procureurs soutiennent qu'Insys rémunérait des prescripteurs via des programmes de speakers fictifs ou biaisés et utilisait son centre de remboursement pour obtenir des autorisations de prise en charge de Subsys.

Attribution
Accused

Sources · 2

  1. [1]
    U.S. Department of Justice, District of MassachusettsFounder and Former Chairman of the Board of Insys Therapeutics Sentenced to 66 Months in PrisonOfficial statementVery high reliability
  2. [2]
    U.S. Department of JusticeOpioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global ResolutionCompany documentVery high reliability

Last verified: 19 September 2026

Add to this entry

05

2 mai 2019

Condamnation pour complot RICO

Conviction

Un jury fédéral déclare Kapoor coupable de complot RICO avec plusieurs autres dirigeants d'Insys.

Legal status — source text
Conviction
Attribution
Accused

Sources · 2

  1. [1]
    U.S. Department of Justice, District of MassachusettsFounder and Former Chairman of the Board of Insys Therapeutics Sentenced to 66 Months in PrisonOfficial statementVery high reliability
  2. [2]
    U.S. Court of Appeals for the First Circuit / JustiaUnited States v. Simon, No. 20-1368Court decisionVery high reliability

Last verified: 19 September 2026

Add to this entry

07

2019

Post-trial : le tribunal écarte certains predicate findings mais maintient le verdict RICO

Conviction

Le tribunal de district écarte certaines conclusions du jury relatives aux predicates Controlled Substances Act et honest-services pour Kapoor et d'autres, tout en laissant intact le verdict de complot RICO fondé notamment sur mail/wire fraud.

Attribution
Accused

Sources · 1

  1. [1]
    U.S. Court of Appeals for the First Circuit / JustiaUnited States v. Simon, No. 20-1368Court decisionVery high reliability

Last verified: 19 September 2026

Add to this entry

09

24 octobre 2017

Inculpation dans le dossier Subsys

Formally charged

Kapoor est ajouté par superseding indictment au dossier fédéral visant des dirigeants d'Insys pour un système présumé de kickbacks et de fraude autour de Subsys, spray de fentanyl.

State of the evidence
Documented
Attribution
Accused

Sources · 2

  1. [1]
    U.S. District Court for the District of Delaware / JustiaInsys Liquidation Trust v. Kapoor — Proposed FindingsCourt recordHigh reliability
  2. [2]
    U.S. Department of Justice, District of MassachusettsFounder and Former Chairman of the Board of Insys Therapeutics Sentenced to 66 Months in PrisonOfficial statementVery high reliability

Last verified: 19 September 2026

Add to this entry

06

juin 2019

Insys conclut un règlement global de 225 millions de dollars puis se place sous Chapter 11

Conviction — against Insys Therapeutics

Protagonist not prosecuted — these proceedings are not counted in their formal charges or convictions.

Insys accepte un règlement global de 225 millions de dollars avec le gouvernement, incluant un plaidoyer de culpabilité de sa filiale opérationnelle, puis dépose une demande de protection Chapter 11 quelques jours plus tard.

State of the evidence
Documented
Person targeted by the proceedings
Insys Therapeutics
Role of the person profiled
Protagonist not prosecuted

Sources · 2

  1. [1]
    U.S. Department of JusticeOpioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global ResolutionCompany documentVery high reliability
  2. [2]
    U.S. Securities and Exchange CommissionInsys Therapeutics Chapter 11 Filing — Form 8-KRegulatory filingVery high reliability

Last verified: 19 September 2026

Add to this entry

08

novembre 2015–janvier 2017

Retour comme CEO d'Insys

No legal proceedings

Après avoir longtemps présidé le conseil, Kapoor reprend la fonction de CEO d'Insys en novembre 2015.

State of the evidence
Documented
Legal status — source text
Not applicable
Attribution
Direct responsibility

Sources · 1

  1. [1]
    U.S. Securities and Exchange CommissionInsys Therapeutics 2016 Proxy StatementRegulatory filingVery high reliability

Last verified: 19 September 2026

Add to this entry

II. Documented background

Documented biographical or institutional milestones (elections, appointments, foundings, acquisitions…). These are not controversies and are not counted as such.

  1. 9 janvier 2017

    Retraite des fonctions de CEO et chairman d'Insys

    Insys annonce que Kapoor quitte les fonctions de président, CEO et chairman, tout en demeurant alors administrateur et président du comité scientifique et R&D.

    Sources · 2
    1. U.S. Securities and Exchange Commission / Insys Therapeutics — Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman
    2. U.S. Securities and Exchange Commission — Insys Therapeutics 2017 Proxy Statement
  2. 1990–2016

    Fondateur, principal actionnaire et président d'Insys Therapeutics

    Kapoor est présenté par Insys comme fondateur, président du conseil et principal actionnaire; en 2016, ses avoirs directs et via trusts représentent environ 67,3 % des actions selon le proxy.

    Sources · 1
    1. U.S. Securities and Exchange Commission — Insys Therapeutics 2016 Proxy Statement
  3. 1993–2002

    Direction d'OptionCare et d'Akorn

    Il dirige OptionCare dans les années 1990 et exerce à plusieurs reprises comme CEO d'Akorn, tout en présidant divers conseils de sociétés pharmaceutiques.

    Sources · 2
    1. U.S. Securities and Exchange Commission — Insys Therapeutics 2016 Proxy Statement
    2. U.S. Securities and Exchange Commission — Insys Therapeutics 2017 Proxy Statement
  4. 1990

    Création d'EJ Financial Enterprises et investissements pharmaceutiques

    Kapoor crée EJ Financial Enterprises et développe parallèlement plusieurs participations et activités d'investissement dans les sociétés pharmaceutiques.

    Sources · 1
    1. U.S. Securities and Exchange Commission — Insys Therapeutics 2016 Proxy Statement
  5. années 1960–1970

    Formation en pharmacie et chimie médicinale

    Kapoor obtient un B.S. en pharmacie à Bombay University puis un doctorat en chimie médicinale à SUNY Buffalo avant de construire une carrière dans les biopharmaceutiques.

    Sources · 1
    1. U.S. Securities and Exchange Commission — Insys Therapeutics 2016 Proxy Statement

III. Constellation of documented links

No documented link with another published profile for now.

Two profiles are linked when a documented controversy of one names the other. The link points to that controversy and its sources; it does not indicate a personal relationship.

IV. Has something changed?

A new court decision, a missing source, a mistake? Tell us what should be updated: every request is read by the editorial team.

Update request

John Kapoor

Say which controversy is concerned and, if possible, give a source. Between 10 and 2,500 characters.

0 / 2500

To prevent abuse, the approximate location of your connection is recorded with your request.

iPhone and iPad

Install Controversia

  1. Tap Share
  2. then Add to Home Screen

Tap Share, then Add to Home Screen.